Biogen Inc.
BIIB · Nasdaq
- $217.15
- $32.12B
- Open
- —
- —
- $215.56 - $222.25
- $135.39 - $225.80
- —
- —
- 629.90K
About Biogen Inc.
Biogen is identified in the supplied material as a public company whose stock is analyzed, and its reported financials show a biopharmaceutical business generating $9.9 billion of FY2025 revenue and $1.3 billion of net income, versus $9.7 billion and $1.6 billion in FY2024. The evidence supplied does not identify its medicines, therapeutic franchises, operating segments, segment revenue contributions, customer groups, geographic mix, workforce, or commercial scale. Therefore, the supported overview is limited to its company-level financial scale: roughly $10 billion of annual revenue and positive net income in the latest reported year.
Notable Price Movement
- Aug 3-7$207.942.46%
Biogen rose $2.84, or 1.38%, over the stated week, from $205.61 to $208.45. The move was not linear: the stock first advanced to $209.23 on July 29, slipped to $207.93 on July 30 and $202.95 on July 31, then reached a weekly low of $201.82 on August 3 before rebounding $6.63 on August 4. The only supplied company-specific driver was The Motley Fool’s report that Biogen handily beat analyst estimates on both revenue and earnings, which fits the final rebound. No details on the beat, guidance, pipeline, or market backdrop were supplied, so no additional cause can be assigned.
